Applied Therapeutics, Inc. Reports Net Loss of $29.6 Million in Q2 2023

Applied Therapeutics, Inc.(APLT), a biopharmaceutical company focu sed on developing transformative therapies for patients with serious medical conditions, has released its condensed financial statements for the second quarter of 2023. The company's financial performance highlights a net loss of $29.6 million for the quarter, along with revenue of $10.7 million. These figures shed light on the company's financial health and its progress in advancing its innovative treatments.

Net Loss of $29.6 Million

Applied Therapeutics faced a net loss of $29.6 million in the second quarter of 2023, reflecting the costs associated with research and development efforts, as well as general administrative expenses. This figure is a significant change compared to the net loss of $25.9 million reported for the same period in 2022. Despite the increase in net loss, the company remains focused on its strategic initiatives to drive growth and innovation in the biopharmaceutical sector.

Revenue Reaches $10.7 Million